Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 May 7.

Published in final edited form as: Neuropharmacology. 2010 Jan 6;58(7):972–980. doi: 10.1016/j.neuropharm.2009.12.017

Animals were treated as described in the legend to Figure 5. Death was recorded. Animals were included in the study if they survived up to the initiation of treatment with saline (Cont) or with rtPA or rtPA together with the 6- or 18-aa-Tyr PAI-1 derived peptides. The number of deaths in each group was recorded. The mean from 16 animals/group is shown. Panel B: Preservation of neurological function. Animals were treated as described in the legend to Figure 5. The neurological score was measured 24 hours after induction of ischemia in animals treated with saline (Cont), rtPA or rtPA together with 18-aa-Tyr, as described in Methods. The mean ± SEM of data from 12 animals/group is shown.

Animals were treated as described in the legend to Figure 5. Death was recorded. Animals were included in the study if they survived up to the initiation of treatment with saline (Cont) or with rtPA or rtPA together with the 6- or 18-aa-Tyr PAI-1 derived peptides. The number of deaths in each group was recorded. The mean from 16 animals/group is shown. Panel B: Preservation of neurological function. Animals were treated as described in the legend to Figure 5. The neurological score was measured 24 hours after induction of ischemia in animals treated with saline (Cont), rtPA or rtPA together with 18-aa-Tyr, as described in Methods. The mean ± SEM of data from 12 animals/group is shown.